MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload

Ji,Yue; Qiu,Ming; Shen,Yejiao; Gao,Li; Wang,Yaqing; Sun,Wei; Li,Xinli; Lu,Yan; Kong,Xiangqing

doi:10.3892/ijmm.2018.3428

MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload

Authors:
- Yue Ji
- Ming Qiu
- Yejiao Shen
- Li Gao
- Yaqing Wang
- Wei Sun
- Xinli Li
- Yan Lu
- Xiangqing Kong
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: January 25, 2018 https://doi.org/10.3892/ijmm.2018.3428
Pages: 1909-1916
Copyright: © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miRNA/miR) dysregulation has been reported to be fundamental in the development and progression of cardiac hypertrophy and fibrosis. In the present study, miR-327 levels in fibroblasts were increased in response to cardiac hypertrophy induced by transverse aortic constriction with prominent cardiac fibrosis, particularly when compared with the levels in unstressed cardiomyocytes. In neonatal rat cardiac fibroblasts, induced expression of miR-327 upregulated fibrosis-associated gene expression and activated angiotensin II-induced differentiation into myofibroblasts, as assessed via α-smooth muscle actin staining. By contrast, miR-327 knockdown mitigated angiotensin II-induced differentiation. Cardiac fibroblast proliferation was not affected under either condition. In a mouse model subjected to transverse aortic constriction, miR-327 knockdown through tail-vein injection reduced the development of cardiac fibrosis and ventricular dysfunction. miR-327 was demonstrated to target integrin β3 and diminish the activation of cardiac fibroblasts. Thus, the present study supports the use of miR-327 as a therapeutic target in the reduction of cardiac fibrosis.

View Figures

View References

1	Huang S, Zou X, Zhu JN, Fu YH, Lin QX, Liang YY, Deng CY, Kuang SJ, Zhang MZ, Liao YL, et al: Attenuation of microrna-16 derepresses the cyclins d1, d2 and e1 to provoke cardiomyocyte hypertrophy. J Cell Mol Med. 19:608–619. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chien KR, Shimizu M, Hoshijima M, Minamisawa S and Grace AA: Toward molecular strategies for heart disease-past, present, future. Jpn Circ J. 61:91–118. 1997. View Article : Google Scholar : PubMed/NCBI
3	Tao L, Bei Y, Chen P, Lei Z, Fu S, Zhang H, Xu J, Che L, Chen X, Sluijter JP, et al: Crucial role of mir-433 in regulating cardiac fibrosis. Theranostics. 6:2068–2083. 2016. View Article : Google Scholar : PubMed/NCBI
4	Thannickal VJ, Zhou Y, Gaggar A and Duncan SR: Fibrosis: Ultimate and proximate causes. J Clin Invest. 124:4673–4677. 2014. View Article : Google Scholar : PubMed/NCBI
5	Thum T and Lorenzen JM: Cardiac fibrosis revisited by microRNA therapeutics. Circulation. 126:800–802. 2012. View Article : Google Scholar : PubMed/NCBI
6	Olson EN: Micrornas as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med. 6:239ps32014. View Article : Google Scholar : PubMed/NCBI
7	Yang X, Wu D, Du H, Nie F, Pang X and Xu Y: MicroRNA-135a is involved in podocyte injury in a transient receptor potential channel 1-dependent manner. Int J Mol Med. 40:1511–1519. 2017. View Article : Google Scholar : PubMed/NCBI
8	Zhou B, Li H and Shi J: miR-27 inhibits the NF-κB signaling pathway by targetingleptin in osteoarthritic chondrocytes. Int J Mol Med. 40:523–530. 2017. View Article : Google Scholar : PubMed/NCBI
9	Thum T: Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol. 11:655–663. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tao H, Yang JJ and Shi KH: Non-coding RNAs as direct and indirect modulators of epigenetic mechanism regulation of cardiac fibrosis. Expert Opin Ther Targets. 19:707–716. 2015. View Article : Google Scholar : PubMed/NCBI
11	Kumarswamy R and Thum T: Non-coding RNAs in cardiac remodeling and heart failure. Circ Res. 113:676–689. 2013. View Article : Google Scholar : PubMed/NCBI
12	Espinoza-Lewis RA: Wang DZ. MicroRNAs in heart development. Curr Top Dev Biol. 100:279–317. 2012. View Article : Google Scholar : PubMed/NCBI
13	Small EM and Olson EN: Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:336–342. 2011. View Article : Google Scholar : PubMed/NCBI
14	Shi J, Wang L, Lu Y, Ji Y, Wang Y, Dong K, Kong X and Sun W: Protective effects of seabuckthorn pulp and seed oils against radiation-induced acute intestinal injury. J Radiat Res. 58:24–32. 2017. View Article : Google Scholar :
15	Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XH and De Windt LJ: Nfatc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem. 283:22295–22303. 2008. View Article : Google Scholar : PubMed/NCBI
16	Lu Y, Zhu X, Li J, Fang R, Wang Z, Zhang J, Li K, Li X, Bai H, Yang Q, et al: Glycine prevents pressure overload induced cardiac hypertrophy mediated by glycine receptor. Biochem Pharmacol. 123:40–51. 2017. View Article : Google Scholar
17	Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, et al: Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 19:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
18	Cheng Y, Zhu Y, Zhang J, Duan X and Zhang Y: Large accumulation of collagen and increased activation of mast cells in hearts of mice with hyperlipidemia. Arq Bras Cardiol. 109:404–409. 2017.In English, Portuguese. PubMed/NCBI
19	Irelan JT, Wu MJ, Morgan J, Ke N, Xi B, Wang X, Xu X and Abassi YA: Rapid and quantitative assessment of cell quality, identity, and functionality for cell-based assays using real-time cellular analysis. J Biomol Screen. 16:313–322. 2011. View Article : Google Scholar : PubMed/NCBI
20	Xing D and Orsulic S: A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA. 102:6936–6941. 2005. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^C T method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Heineke J and Molkentin JD: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 7:589–600. 2006. View Article : Google Scholar : PubMed/NCBI
23	Maillet M, van Berlo JH and Molkentin JD: Molecular basis of physiological heart growth: Fundamental concepts and new players. Nat Rev Mol Cell Biol. 14:38–48. 2013. View Article : Google Scholar
24	Dirkx E, Gladka MM, Philippen LE, Armand AS, Kinet V, Leptidis S, El Azzouzi H, Salic K, Bourajjaj M, da Silva GJ, et al: Nfat and mir-25 cooperate to reactivate the transcription factor hand2 in heart failure. Nat Cell Biol. 15:1282–1293. 2013. View Article : Google Scholar : PubMed/NCBI
25	Melman YF, Shah R and Das S: Micrornas in heart failure: Is the picture becoming less mirky. Circ Heart Fail. 7:203–214. 2014. View Article : Google Scholar : PubMed/NCBI
26	Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P, Contaldi C, Saccani Jotti G, Franzone A, Galastri L, et al: Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 63:920–927. 2014. View Article : Google Scholar
27	Wang J, Liew OW, Richards AM and Chen YT: Overview of MicroRNAs in cardiac hypertrophy, fibrosis, and apoptosis. Int J Mol Sci. 17:pii: E7492016. View Article : Google Scholar
28	Wu C, Dong S and Li Y: Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload. Int J Mol Med. 35:893–900. 2015. View Article : Google Scholar : PubMed/NCBI
29	Ling H, Fabbri M and Calin GA: Micrornas and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
30	Gacoń J, Kabłak-Ziembicka A, Stępień E, Enguita FJ, Karch I, Derlaga B, Żmudka K and Przewłocki T: Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol. 74:280–288. 2016. View Article : Google Scholar
31	Gao H, Guddeti RR, Matsuzawa Y, Liu LP, Su LX, Guo D, Nie SP, Du J and Zhang M: Plasma levels of microRNA-145 are associated with severity of coronary artery disease. PLoS One. 10:e01234772015. View Article : Google Scholar : PubMed/NCBI
32	Gao W, He HW, Wang ZM, Zhao H, Lian XQ, Wang YS, Zhu J, Yan JJ, Zhang DG, Yang ZJ and Wang LS: Plasma levels of lipometabolism-related miR-122 and mir-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis. 11:552012. View Article : Google Scholar : PubMed/NCBI
33	Wang F, Long G, Zhao C, Li H, Chaugai S, Wang Y, Chen C and Wang DW: Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med. 11:2222013. View Article : Google Scholar : PubMed/NCBI
34	Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et al: MicroRNA-21 contributes to myocardial disease by stimulating map kinase signalling in fibroblasts. Nature. 456:980–984. 2008. View Article : Google Scholar : PubMed/NCBI
35	Wang J, Huang W, Xu R, Nie Y, Cao X, Meng J, Xu X, Hu S and Zheng Z: MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med. 16:2150–2160. 2012. View Article : Google Scholar : PubMed/NCBI
36	Ye Y, Perez-Polo JR, Qian J and Birnbaum Y: The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics. 43:534–542. 2011. View Article : Google Scholar
37	Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, Wang D, Krall TJ, Delphin ES and Zhang C: MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem. 284:29514–29525. 2009. View Article : Google Scholar : PubMed/NCBI
38	Kong P, Christia P and Frangogiannis NG: The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 71:549–574. 2014. View Article : Google Scholar
39	Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K, González A, Thum T, Diez J, Jaisser F, et al: Myocardial fibrosis: Biomedical research from bench to bedside. Eur J Heart Fail. 19:177–191. 2017. View Article : Google Scholar : PubMed/NCBI
40	Weber KT, Sun Y, Bhattacharya SK, Ahokas RA and Gerling IC: Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 10:15–26. 2013. View Article : Google Scholar
41	Esposito G, Perrino C, Schiattarella GG, Belardo L, di Pietro E, Franzone A, Capretti G, Gargiulo G, Pironti G, Cannavo A, et al: Induction of mitogen-activated protein kinases is proportional to the amount of pressure overload. Hypertension. 55:137–143. 2010. View Article : Google Scholar
42	Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T and Molkentin JD: Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 103:670–677. 2001. View Article : Google Scholar : PubMed/NCBI
43	Peterson KL: Pressure overload hypertrophy and congestive heart failure. Where is the 'Achilles' heel'. J Am Coll Cardiol. 39:672–675. 2002. View Article : Google Scholar : PubMed/NCBI
44	Rose BA, Force T and Wang Y: Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol Rev. 90:1507–1546. 2010. View Article : Google Scholar : PubMed/NCBI
45	Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie K, Li J, Liu R, Zhang T, Xie N, et al: Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells. Mol Cell Proteomics. 10:M110 0053972011. View Article : Google Scholar : PubMed/NCBI
46	Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, et al: In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 24:45–58. 2013. View Article : Google Scholar : PubMed/NCBI
47	Mazalouskas M, Jessen T, Varney S, Sutcliffe JS, Veenstra-VanderWeele J, Cook EH Jr and Carneiro AM: Integrin β3 haploinsufficiency modulates serotonin transport and antidepressant-sensitive behavior in mice. Neuropsychopharmacology. 40:2015–2024. 2015. View Article : Google Scholar : PubMed/NCBI